Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied

Simopekka Vänskä, Tapio Luostarinen, Iacopo Baussano, Dan Apter, Tiina Eriksson, Kari Natunen, Pekka Nieminen, Jorma Paavonen, Ville N Pimenoff, Eero Pukkala, Anna Söderlund-Strand, Gary Dubin, Geoff Garnett, Joakim Dillner, Matti Lehtinen, Simopekka Vänskä, Tapio Luostarinen, Iacopo Baussano, Dan Apter, Tiina Eriksson, Kari Natunen, Pekka Nieminen, Jorma Paavonen, Ville N Pimenoff, Eero Pukkala, Anna Söderlund-Strand, Gary Dubin, Geoff Garnett, Joakim Dillner, Matti Lehtinen

Abstract

Background: Human papillomavirus (HPV) vaccination of girls with very high (>90%) coverage has the potential to eradicate oncogenic HPVs, but such high coverage is hard to achieve. However, the herd effect (HE) depends both on the HPV type and the vaccination strategy.

Methods: We randomized 33 Finnish communities into gender-neutral HPV16/18 vaccination, girls-only HPV16/18 vaccination, and hepatitis B virus vaccination arms. In 2007-2010, 11 662 of 20 513 of 40 852 of 39 420 resident boys/girls from 1992 to 1995 birth cohorts consented. In 2010-2014, cervicovaginal samples from vaccinated and unvaccinated girls at age 18.5 years were typed for HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68. Vaccine efficacy for vaccinated girls, HE for unvaccinated girls, and the protective effectiveness (PE) for all girls were estimated. We extended the community-randomized trial results about vaccination strategy with mathematical modeling to assess HPV eradication.

Results: The HE and PE estimates in the 1995 birth cohort for HPV18/31/33 were significant in the gender-neutral arm and 150% and 40% stronger than in the girls-only arm. Concordantly, HPV18/31/33 eradication was already predicted in adolescents/young adults in 20 years with 75% coverage of gender-neutral vaccination. With the 75% coverage, eventual HPV16 eradication was also predicted, but only with the gender-neutral strategy.

Conclusions: Gender-neutral vaccination is superior for eradication of oncogenic HPVs.

Trial registration: ClinicalTrials.gov NCT00534638.

Keywords: elimination; eradication; gender-neutral vaccination; herd effects; human papillomavirus.

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Herd effects (HEs) induced by human papillomavirus (HPV) vaccination. The first order HE from vaccinated girls to unvaccinated boys (girls-only vaccination), and from both vaccinated girls and boys to unvaccinated boys and girls (gender-neutral vaccination), as well as the second order HE effects from unvaccinated but herd-protected individuals are visualized (top panel). Herd effects take place towards younger HPV-vaccinated birth cohorts by increasing the number of vaccinated birth cohorts from HPV-infected ones (bottom panel). Herd effects between differentially protected parts of population are visualized (right panel).
Figure 2.
Figure 2.
Prevalence reduction of human papillomavirus (HPV) types 18/31/33 in unvaccinated 18-year-old females by birth cohorts (1992–1995) and vaccination strategy: (Arm A) gender-neutral (49% girls and 23% boys HPV vaccinated [P for trend .0005]); (Arm B) girls-only (47% girls vaccinated [P for trend .092]); (Arm C) control, hepatitis B virus vaccination (P for trend .447) at the age of 12–15 years in 2007–2010. The trend of reduction by birth cohorts in the gender-neutral Arm A was stronger than that of the girls-only Arm B (P = .0556) or control Arm C (P = .0015).
Figure 3.
Figure 3.
Modeled eradication of human papillomavirus (HPV) types 16 [■], 18 [■], and oncogenic HPV types with moderate (31 of 33) [■] or fast (35) [■] clearance rates by vaccine efficacy ([VE] 95%/80%/50%), with 75% girls-only vaccination coverage, with 50% boys and 75% girls vaccination coverage, and with 75% gender-neutral vaccination coverage.
Figure 4.
Figure 4.
Modeled eradication of human papillomavirus (HPV) types 16 [■], 18 [■], and oncogenic HPV types with moderate (31 of 33) [■] or fast (35) [■] clearance rates by vaccine efficacy ([VE] 95%/80%/50%), with 50% girls-only vaccination coverage, with 25% boys and 50% girls vaccination coverage, and with 50% gender-neutral vaccination coverage.

References

    1. European Medicines Agency. Human medicine European public assessment report (EPAR): Gardasil. Available at: . Accessed 14 October 2019.
    1. European Medicines Agency. Human medicine European public assessment report (EPAR): Cervarix. Available at: . Accessed 14 October 2019.
    1. Luostarinen T, Apter D, Dillner J, et al. . Vaccination protects against invasive HPV-associated cancer. Int J Cancer 2017; 42:2186–7.
    1. Elfström KM, Dillner J, Arnheim-Dahlström L. Organization and quality of HPV vaccination programs in Europe. Vaccine 2015; 33:1673–81.
    1. Williams WW, Lu PJ, O’Halloran A, et al. . Surveillance of vaccination coverage among adult populations - United States, 2015. MMWR Surveill Summ 2017; 66:1–28.
    1. Skufca J, Ollgren J, Artama M, Ruokokoski E, Nohynek H, Palmu AA. The association of adverse events with bivalent human papilloma virus vaccination: a nationwide register-based cohort study in Finland. Vaccine 2018; 36:5926–33.
    1. Kavanagh K, Pollock KG, Cuschieri K, et al. . Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis 2017; 17:1293–302.
    1. Sinka K, Kavanagh K, Gordon R, et al. . HPV vaccine in Scotland. J Epidemiol Commun Health 2014; 68:57–63.
    1. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377:2085–92.
    1. Howell-Jones R, Soldan K, Wetten S, et al. . Declining genital warts in young women in england associated with HPV 16/18 vaccination: an ecological study. J Infect Dis 2013; 208:1397–403.
    1. Brisson M, Bénard É, Drolet M, et al. . Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health 2016; 1:e8–17.
    1. Joura EA, Giuliano AR, Iversen OE, et al. ; Broad Spectrum HPV Vaccine Study A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711–23.
    1. Draper E, Bissett SL, Howell-Jones R, et al. . A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) human papillomavirus vaccines in 12-15 year old girls. PLoS One 2013; 8:e61825.
    1. Faust H, Toft L, Sehr P, et al. . Human papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine 2016; 34:1559–65.
    1. Lehtinen M, Söderlund-Strand A, Vänskä S, et al. . Impact of gender-neutral or girls-only vaccination against human papillomavirus-results of a community-randomized clinical trial (I). Int J Cancer 2018; 142:949–58.
    1. Lehtinen M, Luostarinen T, Vänskä S, et al. . Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: results of a community randomized trial (III). Int J Cancer 2018; 143:2299–310.
    1. Gallagher KE, Howard N, Kabakama S, et al. . Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007–2016. Papillomavirus Res 2017; 4:72–8.
    1. Lehtinen M, Apter D, Baussano I, et al. . Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. Vaccine 2015; 33:1284–90.
    1. Vänskä S, Auranen K, Leino T, et al. . Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach. PLoS One 2013; 8:e72088.
    1. Donner A, Klar N. Confidence interval construction for effect measures arising from cluster randomization trials. J Clin Epidemiol 1993; 46:123–31.
    1. Donner A. Some aspects of the design and analysis of cluster randomized trials. Appl Stat 1998; 47:95–113.
    1. Baussano I, Elfström KM, Lazzarato F, et al. . Type-specific human papillomavirus biological features: validated model-based estimates. PLoS One 2013; 8:e81171.
    1. Artemchuk H, Eriksson T, Poljak M, et al. . Long-term antibody response to human papillomavirus vaccines: up to 12 years of follow-up in the Finnish maternity cohort. J Infect Dis 2019; 219:582–9.
    1. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005; 191(Suppl 1):S97–106.
    1. Brouwer AF, Meza R, Eisenberg MC. Transmission heterogeneity and autoinoculation in a multisite infection model of HPV. Math Biosci 2015; 270:115–25.
    1. Lehtinen M, Dillner J. Clinical HPV vaccine trials and beyond. Nature Rev Clin Oncol 2013; 109:400–10.
    1. Baussano I, Lazzarato F, Ronco G, et al. . How human papillomavirus 16 becomes harder to eliminate than other types: a modelling study. J Infect Dis 2017; 216:366–74.
    1. Gray P, Kann H, Pimenoff VN, et al. . Population-based HPV serosurvey among unvaccinated females reveals HPV16 herd effect postgender-neutral vaccination with moderate vaccination coverage: Follow-up of a community randomised trial. EUROGIN, 4 December 2019, Monaco.
    1. Malmqvist E, Helgesson G, Lehtinen J, Natunen K, Lehtinen M. The ethics of implementing human papillomavirus vaccination in developed countries. Med Health Care Philos 2011; 14:19–27.
    1. Hall MT, Simms KT, Lew JB, et al. . The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health 2019; 4:e19–27.
    1. Elfström KM, Lazzarato F, Franceschi S, Dillner J, Baussano I. Human papillomavirus vaccination of boys and extended catch-up vaccination: effects on the resilience of programs. J Infect Dis 2016; 213:199–205.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir